9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CXCR6 deficiency impairs cancer vaccine efficacy and CD8 + resident memory T-cell recruitment in head and neck and lung tumors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Resident memory T lymphocytes (T RM) are located in tissues and play an important role in immunosurveillance against tumors. The presence of T RM prior to treatment or their induction is associated to the response to anti-Programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) immunotherapy and the efficacy of cancer vaccines. Previous work by our group and others has shown that the intranasal route of vaccination allows more efficient induction of these cells in head and neck and lung mucosa, resulting in better tumor protection. The mechanisms of in vivo migration of these cells remains largely unknown, apart from the fact that they express the chemokine receptor CXCR6.

          Methods

          We used CXCR6-deficient mice and an intranasal tumor vaccination model targeting the Human Papillomavirus (HPV) E7 protein expressed by the TC-1 lung cancer epithelial cell line. The role of CXCR6 and its ligand, CXCL16, was analyzed using multiparametric cytometric techniques and Luminex assays.

          Human biopsies obtained from patients with lung cancer were also included in this study.

          Results

          We showed that CXCR6 was preferentially expressed by CD8 + T RM after vaccination in mice and also on intratumoral CD8 + T RM derived from human lung cancer. We also demonstrate that vaccination of Cxcr6-deficient mice induces a defect in the lung recruitment of antigen-specific CD8 + T cells, preferentially in the T RM subsets. In addition, we found that intranasal vaccination with a cancer vaccine is less effective in these Cxcr6-deficient mice compared with wild-type mice, and this loss of efficacy is associated with decreased recruitment of local antitumor CD8 + T RM. Interestingly, intranasal, but not intramuscular vaccination induced higher and more sustained concentrations of CXCL16, compared with other chemokines, in the bronchoalveolar lavage fluid and pulmonary parenchyma.

          Conclusions

          This work demonstrates the in vivo role of CXCR6-CXCL16 axis in the migration of CD8 + resident memory T cells in lung mucosa after vaccination, resulting in the control of tumor growth. This work reinforces and explains why the intranasal route of vaccination is the most appropriate strategy for inducing these cells in the head and neck and pulmonary mucosa, which remains a major objective to overcome resistance to anti-PD-1/PD-L1, especially in cold tumors.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: not found
          • Article: not found

          Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites.

            Tissue-resident memory T cells (TRMs) in mice mediate optimal protective immunity to infection and vaccination, while in humans, the existence and properties of TRMs remain unclear. Here, we use a unique human tissue resource to determine whether human tissue memory T cells constitute a distinct subset in diverse mucosal and lymphoid tissues. We identify a core transcriptional profile within the CD69+ subset of memory CD4+ and CD8+ T cells in lung and spleen that is distinct from that of CD69- TEM cells in tissues and circulation and defines human TRMs based on homology to the transcriptional profile of mouse CD8+ TRMs. Human TRMs in diverse sites exhibit increased expression of adhesion and inhibitory molecules, produce both pro-inflammatory and regulatory cytokines, and have reduced turnover compared with circulating TEM, suggesting unique adaptations for in situ immunity. Together, our results provide a unifying signature for human TRM and a blueprint for designing tissue-targeted immunotherapies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin.

              Tissue-resident memory T cells (T(RM) cells) provide superior protection against infection in extralymphoid tissues. Here we found that CD103(+)CD8(+) T(RM) cells developed in the skin from epithelium-infiltrating precursor cells that lacked expression of the effector-cell marker KLRG1. A combination of entry into the epithelium plus local signaling by interleukin 15 (IL-15) and transforming growth factor-β (TGF-β) was required for the formation of these long-lived memory cells. Notably, differentiation into T(RM) cells resulted in the progressive acquisition of a unique transcriptional profile that differed from that of circulating memory cells and other types of T cells that permanently reside in skin epithelium. We provide a comprehensive molecular framework for the local differentiation of a distinct peripheral population of memory cells that forms a first-line immunological defense system in barrier tissues.
                Bookmark

                Author and article information

                Journal
                J Immunother Cancer
                J Immunother Cancer
                jitc
                jitc
                Journal for Immunotherapy of Cancer
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2051-1426
                2021
                10 March 2021
                : 9
                : 3
                : e001948
                Affiliations
                [1 ]Université de Paris, PARCC, INSERM U970 , 75006 Paris, France
                [2 ]Equipe Labellisée Ligue contre le Cancer , Paris, France
                [3 ]Institut Curie, PSL Research University, Cellular and Chemical Biology Unit, U1143 INSERM, UMR3666 CNRS , 75248 Paris Cedex 05, France
                [4 ]INSERM U830, Equipe labellisée LNCC, Siredo Oncology Centre, Institut Curie , 75248 Paris Cedex 05, France
                [5 ]Institut Curie, PSL Research University, Department of Translational Research , 75248 Paris Cedex 05, France
                [6 ]departmentDepartment of Pathology , APHP, Hôpital Européen Georges Pompidou , 75015 Paris, France
                [7 ]departmentDepartment of Thoracic Surgery , INSERM UMRS 1138, APHP, Hôpital Europeen Georges Pompidou , 75015 Paris, France
                [8 ]departmentLung Oncology Unit , APHP, Hôpital Européen Georges Pompidou , 75015 Paris, France
                [9 ]departmentImmunology , APHP, Hôpital Europeen Georges Pompidou , Paris, France
                [10 ]departmentDepartment of Pathology , APHP, Hôpital Cochin , 75014 Paris, Île-de-France, France
                [11 ]departmentDepartement Immunologie, Inflammation et Infection , Institut Cochin, INSERM U1016, CNRS UMR8104, Université de Paris , 75014 Paris, Île-de-France, France
                [12 ]departmentCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV , Klinikum der Universität München, LMU Munich, Germany, Member of the German Center for Lung Research (DZL) , Munchen, Germany
                [13 ]German Center for Translational Cancer Research (DKTK), partner site , Munchen, Germany
                [14 ]INSERM UMR 1186, Institut Gustave Roussy, Faculté de Médecine-Université Paris-Sud, Université Paris-Saclay , 94805 Villejuif, France
                [15 ]departmentUnit for Lymphopoiesis, Department of Immunology , Institut Pasteur, INSERM U1223 , 75006 Paris, France
                Author notes
                [Correspondence to ] Professor Eric Tartour; eric.tartour@ 123456aphp.fr

                RG, LJ and ET are joint senior authors.

                Author information
                http://orcid.org/0000-0002-4985-7254
                http://orcid.org/0000-0002-7323-468X
                Article
                jitc-2020-001948
                10.1136/jitc-2020-001948
                7949477
                33692218
                456ed66b-e9f9-450f-a145-17a637555d9a
                © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 24 January 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004097, Fondation ARC pour la Recherche sur le Cancer;
                Award ID: Sign'IT
                Funded by: FundRef http://dx.doi.org/10.13039/100010663, H2020 European Research Council;
                Award ID: 756017
                Funded by: FundRef http://dx.doi.org/10.13039/501100006364, Institut National Du Cancer;
                Award ID: PLBio
                Award ID: Siric Carpem
                Categories
                Basic Tumor Immunology
                1506
                2434
                Original research
                Custom metadata
                unlocked

                adaptive immunity,cd8-positive t-lymphocytes,vaccination,immunization

                Comments

                Comment on this article